耐多药结核病患者接触者结核病预防治疗的有效性与安全性:系统综述与Meta分析
该系统综述与Meta分析评估耐多药结核病患者接触者接受结核病预防治疗的有效性与安全性,纳入11项研究共1105人。接受预防治疗者进展为结核病的合并相对风险为0.34(95% CI: 0.16-0.72)。完成率83.8%,不良反应率22.9%,停药率6.5%。
要点
- 耐多药结核病患者接触者接受预防治疗可降低结核病进展风险,合并RR为0.34(95% CI: 0.16-0.72)。
- 基于指示病例药敏谱制定的方案合并RR为0.22(95% CI: 0.06-0.84),统一方案为0.49(95% CI: 0.17-1.35),差异未达统计学显著。
- 合并完成率83.8%,不良反应率22.9%,停药率6.5%;排除左氧氟沙星和吡嗪酰胺方案研究后完成率88.0%,不良反应率8.0%,停药率4.0%。
核心结论
- 预防治疗可降低耐多药结核病患者接触者进展为结核病的风险。
- 基于药敏谱制定的预防治疗方案可能带来额外获益。
- 提高完成率和管理不良反应对优化有效性与安全性至关重要。
研究设计与样本
- 系统综述与Meta分析,检索EMBASE、PubMed、Web of Science和Cochrane Library,检索日期为2023年7月24日,无起始日期限制。
- 纳入比较预防治疗与无治疗在耐多药结核病患者接触者中进展为结核病结局的研究。
- 采用改良版纽卡斯尔-渥太华量表评估偏倚风险,使用随机效应Meta分析计算相对风险。
- 共纳入11项研究,涉及1105名个体。
主要发现
- 接受预防治疗者进展为结核病的合并相对风险为0.34(95% CI: 0.16-0.72),对照为无治疗。
- 基于指示病例药敏谱的方案合并相对风险为0.22(95% CI: 0.06-0.84),统一治疗方案为0.49(95% CI: 0.17-1.35),组间差异未达统计学显著。
- 合并完成率为83.8%,不良反应率为22.9%,停药率为6.5%。
- 排除左氧氟沙星和吡嗪酰胺方案研究后,完成率升至88.0%,不良反应率降至8.0%,停药率降至4.0%。
关键数值与推荐
- 纳入标准为比较预防治疗与无治疗在耐多药结核病患者接触者中并报告进展为结核病结局的研究。
- 采用改良版纽卡斯尔-渥太华量表评估偏倚风险。
- 使用随机效应Meta分析计算相对风险,并评估完成率、不良反应率和停药率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contacts of patients with multidrug-resistant tuberculosis (MDR-TB) are at risk of developing TB disease. Tuberculosis preventive treatment (TPT) is an intervention that can potentially reduce this risk. OBJECTIVES: To evaluate the effectiveness and safety of TPT for contacts of patients with MDR-TB. DATA SOURCES: EMBASE, PubMed, Web of Science, and the Cochrane Library were searched for eligible studies on 24 July 2023, without start date restrictions. STUDY ELIGIBILITY CRITERIA: We included studies that compared TPT with no treatment in contacts of patients with MDR-TB and reported outcomes of progression to TB disease. PARTICIPANTS: Contacts of patients with MDR-TB. INTERVENTIONS: TPT. ASSESSMENT OF RISK OF BIAS: A modified version of the Newcastle-Ottawa Scale was used. METHODS OF DATA SYNTHESIS: Random-effects meta-analysis was utilized to calculate the relative risk for disease progression to TB in contacts of patients with MDR-TB who received TPT compared to those who did not. Additionally, completion, adverse effect, and discontinued rates were assessed. RESULTS: Involving 1105 individuals from 11 studies, the pooled relative risk for disease progression in contacts receiving TPT versus those without treatment was 0.34 (95% CI: 0.16-0.72). Subgroup analysis indicated a lower pooled relative risk for regimens based on the drug-resistance profile of the index patients with TB compared to uniform treatment regimens (0.22 [95% CI: 0.06-0.84] vs. 0.49 [95% CI: 0.17-1.35]), although not statistically significant. The pooled completed rate was 83.8%, adverse effect rate was 22.9%, and discontinued rate was 6.5%. After excluding the levofloxacin and pyrazinamide regimen study, the completed rate increased to 88.0%, and adverse effects and discontinued rates decreased to 8.0% and 4.0%, respectively. DISCUSSION: TPT reduces TB disease progression risk in contacts of patients with MDR-TB. Tailored TPT regimens based on drug-resistance profiles may offer additional benefits. Furthermore, efforts to improve completed rates and manage adverse effects are essential for optimizing effectiveness and safety.
引用
- Zhou G, Luo S, He J, et al. Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect. 2023. PMID: 37741621. doi:10.1016/j.cmi.2023.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。